A platelet factor 4 (PF4)-expressing cell line, HELNeo, was derived from the human erythroleukemia cell line, HEL. This was achieved by stable transfection of HEL cells with a construct containing the rat PF4 promoter driving the gene coding for resistance to neomycin, followed by selection of neomycin-resistant clones. HELNeo cells were all nonadhering and about 5% of the cells had polyploid nuclei (r8N). as compared with 1 % in HEL cells. Immunohistochemistry showed that about 90% of the HELNeo cells contained PF4, whereas only -5% of the HEL cells contained PF4. No significant parallel enrichment was observed for other megakaryocytic markers, such as the glycoprotein AST STUDIES of megakaryocyte biochemistry and dif-P ferentiation have been hampered because of the lack of a pure megakaryocytic cell line. Some human erythroleukemic cell lines such as HEL and K562 exhibit myeloid, erythroid, and megakaryocytic markers and have been used to define megakaryocyte function and differentiation. The expression of the megakaryocytic properties of these cell lines'-3 may even be enhanced by exposure to phorbol esters or dimethylsulfoxide (DMSO). Recently, some human cell lines such as MEGOI, DAMI, EST-IU, and CMKl 1-5,4-7 which are enriched with megakaryocyte markers, have been established. Unfortunately, most of these cell lines either fail to produce detectable amounts of megakaryocyte-specific proteins such as platelet factor 4 (PF4) or produce amounts that are small relative to that found in megakaryocytes isolated from bone marrow (BM).
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PF4, a protein unique to megakaryocytes and platelets, serves as an excellent marker for megakaryocytes. We have recently shown that the 1.1-kb 5'-upstream region of the rat PF4 gene drives the lineage-specific expression of several reporter genes in HEL cells and in mouse and rat BM megakaryocytes and This report describes a novel approach using this lineage-specific PF4 promoter for selecting cells with megakaryocytic properties from HEL cells, a multilineage human erythroleukemia cell line that is presumed to consist of multipotential hematopoietic cells arrested early in their differentiation. This was achieved via stable transfection with the PF4 promoter' linked to the gene coding for neomycin," followed by s e l d o n for resistance to the antibiotic. This strategy should prove to be a general method for producing lineage-specific cell lines that may be used to study the function and differentiation of other hematopoietic lineages.
MATERIALS AND METHODS
pPF4Neo was constructed by replacing the human growth hormone (HGH) gene in pPF4GH9 with the neomycin gene. pRSVNeo (generous gift of Dr H. Ruley, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA) was digested with Hind111 and BamHI to obtain the 2.3-kb neomycin gene," which was then ligated to the Ban II/BsbMI-lin&ed pPF4GH by blunt ligation. The orientation of insertion was confumed by sequencing. A linear PF4Neo DNA insert containing the PF4 promoter and the neomycin gene was obtained by digesting pPF4Neo with Nde I and EcoRI.
The human erythroleukemia cell line (HEL) was grown as described previously.' The HELNeo cell line was obtained by the following procedure. Early-passaged HEL cells
Plasmids.
Cell lines and cell culture. complex llb/llla, von Willebrand factor, and platelet activation-dependent granule to external membrane glycoprotein (PADGEM), which were present to a similar extent in both HEL and HELNeo lines. The increased expression of PF4 in HELNeo cells was confirmed by transient expression assays and was associated with a fivefold increase in trans-acting factors binding to the PF4 promoter. These cells should be a rich source for purifying trans-acting factors binding to the PF4 gene. Moreover, our study shows how a lineage-specific promoter may be used to generate lineage-specific cell lines from a multilineage hematopoietic cell line. 0 1993 by The American Society of Hematology.
were transfected by electroporation as described beforeg in the presence of 55 pg of linear pPF4Neo DNA and cultured for 5 days. The antibiotic G-418 (GIBCO, Grand Island, NY) was then added to the medium at a concentration of I .2 mg/mL and the cells cultured in the presence of the antibiotic for 14 days, the length of time found by preliminary experiments to be required to kill all untransfected cells. The surviving cell line obtained, HELNeo, grew either in the presence or absence of G-4 18.
The integration of the neomycin gene into the genome of cells grown in culture for 3 months after transfection was shown by using the PCR. Genomic DNA was prepared" from HEL or HELNeo cells. The primers GTCGAGCACAGCTGCGCAAG (sense) and CCGGATGAAT-GTCAGCTACT (antisense) were designed to amplify 5 10 bp in the neomycin gene.
Electroporation was used for transient expression experiments of HELNeo or HEL cells using pPF4GH. The conditions used as well as the HGH assay are described in Ravid et al. 9 The cells were also transfected with pSVTKGH9 and assayed for HGH production, showing that the HGH level detected in different transfection experiments differed by up to 20%.
Total RNA was isolated from HEL or HELNeo cells and Northern blot analyses were performed as described in Ravid et al?
Cells were spun down, washed with buffer containing citrate, adenosine, and theophyllin (CATCH)," resuspended in a formaldehyde solution (2% in phosphate-buffered saline [PBS]) containing 0.05% Triton X-100, and fixed for 30 minutes at room temperature. The cells were washed twice with CATCHL3 and stained with one of the following first antibodies (100-to 250-fold dilution in CATCH) for 30 minutes at room temperature: rabbit antihuman PF4 (Assera PF4; Diagnostica Stago, Asnieres, France), antirabbit IgG conjugated to fluorescein isothiocyanate (FITC) (500-fold dilution in CATCH) for 30 minutes at room temperature. The cells were washed twice with CATCH and analyzed by fluorescence microscopy (Nikon, Inc, Garden City, NJ) and flow cytometry (FACStar Plus, Becton Dickson, Mountain View, CA)R to determine the percentage of fluorescence-positive cells.
Cells were stained with propidium iodide and DNA analysis was performed by flow cytometry as described before."
HEL or HELNeo cells were stained with the anti-PF4 antibody followed by goldconjugated antirabbit IgG and subjected to electron microscope to determine cell structure as well as to determine whether PF4 was located in a-granules.
Nuclear protein extract was prepared as Elecfron microscopy.
MobiMy-shfi assay. (Fig 1) was confirmed using the PCR. Both the HELNeo and H E L cells grew as a suspension culture with a doubling time of 2 4 hours and exhibited a wide variation in cell size. However, the percentage of large cells (2-30 pm in diameter) was greater in HELNeo (10%) than in HEL ( 1%) (Fig 2A) . Electron microscope analysis of the HELNeo cells (Fig 2B) showed occasional cells containing a multilobulated nucleus and a high nuclear-cytoplasmic ratio. T h e predominant cells displayed frequent budding of the cytoplasmic membrane but no demarcation membranes. T h e cytoplasm was devoid of a-granules in both H E L and HELNeo cells. 
RESULTS

Selection
Ploidv anal.vsis. Ploidy analysis of exponentially growing
HELNeo cells is summarized in Table I . The percentage of HELNeo cells with ploidy 28N was about fivefold higher than in HEL cells. Although the HELNeo cells were predominantly 2N, -5% of the cells were 28N. The addition of DMSO did not alter the high-ploidy class in the HELNeo cells. To exclude the possibility that the cells 28N were not merely aggregates, the cells were sorted and found to besingle cells after observation by microscope.
Northern blot analyses of HEL and HELNeo cells showed a fourfold increase in the level of the PF4 message in the HELNeo cells as compared with that found in HEL cells (Fig 3) . This message could be further increased by the addition of DMSO. The cellular distribution of the PF4 protein and other megakaryocytic markers was examined by flow cytometer analysis and is shown in Table  2 . About 90% of the HELNeo cells contained PF4, whereas only -5% of the HEL cells contained PF4. No significant parallel enrichment was observed for glycoprotein (GP) Ilb/ Illa, vWF, or PADGEM. However, it should be pointed out that the percentage of HEL cells showing fluorescent labeling with these megakaryocytic antibodies was variable (up to 10% of the cells staining) and depended on the batch and passage ofcells used. The addition of DMSO to the HEL and HELNeo cells did not increase the percentage of the cells positive for PF4, vWF, PADGEM, or Ilb/llla (data not shown).
Transcriptional regulation of [lie PF4 gene in the HELNeo cells. To understand the mechanism by which HELNeo cells produced increased amounts of PF4 mRNA, the transcriptional regulation of the PF4 gene was studied in the HELNeo cells. Our previous studies showed that the 5'-up stream regions of the rat and human PF4 genes contained some homologous cis-acting elements? Two regions with seMegakaryocytic markers. Immunofluorescence assays were performed as described under Materials and Methods. Results are expressed as mean ? SD. The number of experiments performed is indicated in parentheses. quence identity in the PF4 promoter were shown to be enhancer domains: P,, extending from -137 to -120 in the rat PF4 gene, and from -134 to -I 17 in human; and P2, extending from -270 to -257 in rat and -299 to -286 in human? The previously described plasmid PF4GH9 containing the rat 1.1-kb PF4 promoter or altered constructs lacking P, or P2 were linked to the HGH geneg and used for transient expression experiments in HELNeo cells. As shown in Table 3 , a higher level of HGH expression was detected in the HELNeo cells, whereas removal of the enhancer domains P, or P2 resulted in a decrease in the transcriptional activity. Mobility-shift assay showed binding of HELNeo nuclear protein to the P2 region (Fig 4A) . This binding was found to be specific for the P2 region because excess unlabeled probe, but not randomly mmbled duplex oligonucleotides, competed w i t h the labeled probe. The amount of the P2 probe shifted with the HELNeo nuclear extract was about fivefold higher than with The cells were transfected and cultured as outlined in Materials and Methods. The level of HGH secreted is an average of two experiments. pPF4GHbPl represents pPF4GH with deletions of the rat-enhancer domain P1 (from -137 to -120). whereas pPF4GH,P2 represents pPF4GH with deletions of the rat enhancer P2 (from -270 to -257). A description of these constructs is presented in detail in Ravid et al.g Expression of HGH in HEL cells. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From RAVID ET AL firmed by us in this report. However, stable transfection of HEL cells with the 5'-upstream 1. I-kb region of the rat PF4 gene linked to the neomycin gene, followed by selection for neomycin resistance cells, produced a cell line expressing PF4 in 90% of cells. The PF4 in HELNeo cells seemed to be localized in the cytosol as no a-granules were detected by electron microscope analysis. Such cytoplasmic PF4 was shown first by Adachi et al' in their CMKl l-5 human cell line.
We next examined the possibility that our selection procedure had simultaneously enriched for cells expressing other megakaryocyte markers such as vWF, PADGEM, or nuclear polyploidy. We found that the HELNeo cells were enriched for PF4 but not for vWF or PADGEM. Furthermore, although large, polyploid cells were fivefold more common in HELNeo than in the parent HEL cells, these cells never constituted more than 5% of the total number of cells. This failure to enrich for other megakaryocyte properties has several possible explanations. The first is that the parental HEL cells may be abnormal because of their leukemic origin and lack much of the genetic program for complete megakaryocyte differentiation. Because our selection procedure was designed to expand the PF4-expressing cells that existed in the original HEL population, the HELNeo line may have originated from the small number of PF4-expressing cells in the parental HEL line, but these cells were genetically unable to form a-granules, coexpress the megakaryocyte proteins vWF or PADGEM, or undergo significant ploidization. A second possibility is that the multiple markers of megakaryocyte differentiation are not coordinately regulated and may be expressed independently of each other. Therefore, the enrichment of PF4-expressing cells in HELNeo would not be expected to enrich for all other megakaryocyte properties. The final possibility is that the PFCexpressing cells that have been enriched in the HELNeo line were derived from cells in the HEL parent line that have undergone only the early part of their differentiation program and express only IIb/IIIa and PF4. It has been suggested that in normal human megakaryocyte differentiation CD34+ cells first become GPIIIa positive and only later develop a-granules, demarcation membranes, and polyploidy. 16 We are unable to distinguish between these possibilities for our HELNeo line at the present time. Because these problems have not been addressed for any megakaryocyte line, we urge caution in using megakaryocyte cell lines to make any general statements regarding megakaryocyte differentiation. Instead, we believe that these megakaryocyte cell lines are best used to study the regulation of specific megakaryocyte proteins such as PF4 or IIb/IIIa.
Therefore, the HELNeo cells should prove to be valuable for studying the transcriptional regulation of the PF4 gene and especially as a potential source for purifying and characterizing transacting factors regulating the expression of this gene. We have shown in the HELNeo cells an increased level of a transacting factor that binds to a strong enhancer domain, P2, in the 5'-upstream region of the PF4 gene. A similar increase was observed when the HEL cells were induced to differentiate by DMSO, implying the importance of the P2 binding factor for high-level expression of the PF4 gene. This demonstration that a lineage-specific promoter allows the selection of cells with lineage-specific properties should provide a promising alternative source of cells for the study of cellspecific gene regulation.
